Trevi Therapeutics Announces The Issuance Of Two Patents Covering The Oral Sustained Release Formulation Of Nalbuphine ER
8/14/2014 8:05:09 AM
NEW HAVEN, Conn.--(BUSINESS WIRE)--Trevi Therapeutics, Inc. (“Trevi”), a clinical stage biotechnology company developing Nalbuphine ER for chronic pruritus conditions, today announced that it has received two issued U.S. patents with claims protecting the oral sustained release formulation of nalbuphine. The patent numbers are 8,771,732 and 8,765,175.
The Company believes that both of these patents will be Orange Book-listable. These two patents complement two additional issued formulation patents, as well as an issued patent protecting the method of use of Nalbuphine ER in the “Methods for Treatment of Pruritus,” which expires in December 2032. Trevi continues to prosecute additional claims to further enhance its existing patent estate protecting Nalbuphine ER in itch.
Help employers find you! Check out all the jobs and post your resume.
comments powered by